An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02376751|
Expanded Access Status : No longer available
First Posted : March 3, 2015
Last Update Posted : June 8, 2016
This is an open-label, multicenter expanded access protocol to allow patients with a confirmed diagnosis of Lysosomal Acid Lipase (LAL) Deficiency in the United States (US), access to sebelipase alfa (recombinant lysosomal acid lipase [rhLAL]) until commercial product is available.
Patients enrolled in the expanded access protocol will receive 1 mg/kg intravenous infusions of sebelipase alfa every other week.
|Condition or disease||Intervention/treatment|
|Lysosomal Acid Lipase Deficiency||Drug: sebelipase alfa|
|Study Type :||Expanded Access|
|Official Title:||AN EXPANDED ACCESS PROTOCOL FOR SEBELIPASE ALFA FOR PATIENTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY|
- Drug: sebelipase alfa
Other Name: SBC-102, recombinant human lysosomal acid lipase, rhLAL